These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22820620)

  • 21. Should men with serum prostate-specific antigen < or =4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review.
    Pepe P; Panella P; D'Arrigo L; Savoca F; Pennisi M; Aragona F
    Oncology; 2006; 70(2):81-9. PubMed ID: 16601365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
    Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
    Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases.
    Gomez-Guerra LS; Martinez-Fierro ML; Alcantara-Aragon V; Ortiz-Lopez R; Martinez-Villarreal RT; Morales-Rodriguez IB; Garza-Guajardo R; Ponce-Camacho MA; Rojas-Martinez A
    BMC Cancer; 2009 Mar; 9():91. PubMed ID: 19317909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen testing in men between 40 and 70 years in Brazil: database from a check-up program.
    Zambon JP; Almeida FG; Conceição RD; Tabone VA; Kashiwagi NM; Ross CL; Carvalho JA
    Int Braz J Urol; 2014; 40(6):745-52. PubMed ID: 25615243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate Health Index density improves detection of clinically significant prostate cancer.
    Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
    BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening.
    Pierre-Victor D; Parnes HL; Andriole GL; Pinsky PF
    Urology; 2021 Sep; 155():62-69. PubMed ID: 34186135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
    Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
    BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.
    Steuber T; Tennstedt P; Macagno A; Athanasiou A; Wittig A; Huber R; Golding B; Schiess R; Gillessen S
    BJU Int; 2019 May; 123(5):826-833. PubMed ID: 30216634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
    Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
    J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val.
    Giri VN; Ruth K; Hughes L; Uzzo RG; Chen DY; Boorjian SA; Viterbo R; Rebbeck TR
    BJU Int; 2011 Feb; 107(3):466-70. PubMed ID: 20735386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (< or =4 ng/ml) and percent free PSA cutoff values of 15 and 20%.
    Pepe P; Panella P; Savoca F; Cacciola A; D'Arrigo L; Dibenedetto G; Pennisi M; Aragona F
    Urol Int; 2007; 78(4):308-12. PubMed ID: 17495487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.
    Castro E; Mikropoulos C; Bancroft EK; Dadaev T; Goh C; Taylor N; Saunders E; Borley N; Keating D; Page EC; Saya S; Hazell S; Livni N; deSouza N; Neal D; Hamdy FC; Kumar P; Antoniou AC; Kote-Jarai Z; ; Eeles RA
    Oncologist; 2016 Jun; 21(6):716-22. PubMed ID: 27151655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.
    Kader AK; Liss MA; Trottier G; Kim ST; Sun J; Zheng SL; Chadwick K; Lockwood G; Xu J; Fleshner NE
    Urology; 2015 Jan; 85(1):165-70. PubMed ID: 25530379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.